Discovery of First-in-class WDR5 PROTACs as a Novel Therapeutic Strategy for MLL-rearranged Leukemias

Icahn School Of Medicine At Mount Sinai, New York NY

Investigators

Linked publications & trials

Abstract

Project Summary This is an application for a Research Supplement to Promote Diversity in Health-Related Research (PA-21-071). The parent R01 grant associated with this application is entitled “Discovery of First-in-class WDR5 PROTACs as a Novel Therapeutic Strategy for MLL-rearranged Leukemias” and supported by the NCI (1R01CA268384-01). Jerrel Catlett is the diversity candidate. He is a US citizen of African-American descent and is currently an MD/PhD student at the Icahn School of Medicine at Mount Sinai, New York. In this project, the candidate will conduct structural biology, biochemistry, biophysics and computational biology studies to characterize PRORAC-induced WDR5-PROTAC-E3 ligase ternary complexes, and to provide new structural insights for the PROTAC-induced ternary complex formation and guide design and development of more effective WDR5 degraders.